Overview
- Tatlisumak, T. et al. (1998) Stroke 29, 190.
Alomone Labs ZD 9379 inhibits NMDA (NR1+NR2A) receptors expressed in Xenopus oocytes.A. Time course of NMDA currents elicited by stimulation with 35 µM glutamate and 35 µM Glycine, every 50 s, while membrane potential was held at -80 mV. 0.1 µM ZD 9379 (#Z-120), applied for 2.5min, as indicated, inhibited current amplitude. B. Superimposed current traces taken from the experiment described in A.
- Tatlisumak, T. et al. (1998) Stroke 29, 190.
- Takano, K. et al. (1997) Stroke 28, 1255.
- Black, S.A. et al. (2014) Front. Cell. Dev. Biol. 2, 45.
ZD 9379 is a neuroprotective, soluble and potent antagonist of the N-methyl-D-aspartate (NMDA) receptor. The compound acts at the glycine site on the NMDA receptor. This site is used as a therapeutic target for acute focal ischemia. ZD 9379 has the ability to pass the blood brain barrier and reduce infract size and frequency in models of ischemic stroke1,2.
The NMDA receptors are a ligand-gated ion channel which is widely distributed in the central nervous system (CNS) and plays an important role in a variety of cellular processes and brain functions such as, synaptic plasticity, addiction and stroke. NMDA receptors mediate physiological functions such as learning and memory formation. They also play a role in glutamate excitotoxicity and are involved in many neurodegenerative conditions including Alzheimer’s disease3.
ZD 9379 (#Z-120) is a highly pure, synthetic, and biologically active compound.
Powered by Bioz
